Neurolixis Inc. has been awarded a $861,000 grant by the US Department of Defense Congressionally Directed Medical Research Program to investigate the effects of NLX-112 as a potential treatment for Machado Joseph disease, a serious and rare genetic movement disorder. NLX-112 is an exceptionally-selective and efficacious serotonin 5-HT1A receptor agonist which has already shown promising activity in models of Parkinson's disease. It is anticipated that NLX-112 could also be beneficial for treatment of other movement disorders, including Machado Joseph disease.

Read the full press release here.